Across TCGA pan-cancer cohorts, GGCTP2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of GGCTP2’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where GGCTP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GGCTP2 is over-expressed in tumor.
HNSC and LUAD are the cancer types where GGCTP2 tumor–normal differential expression is most reproducible.